Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
India
· Delayed Price · Currency is INR 831.55
+9.45 (1.15%)
Apr 17, 2025, 3:30 PM IST
Zydus Lifesciences Revenue
Zydus Lifesciences had revenue of 52.69B INR in the quarter ending December 31, 2024, with 16.96% growth. This brings the company's revenue in the last twelve months to 222.47B, up 16.94% year-over-year. In the fiscal year ending March 31, 2024, Zydus Lifesciences had annual revenue of 195.47B with 13.40% growth.
Revenue (ttm)
222.47B
Revenue Growth
+16.94%
P/S Ratio
3.76
Revenue / Employee
8.26M
Employees
26,921
Market Cap
836.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 195.47B | 23.10B | 13.40% |
| Mar 31, 2023 | 172.37B | 21.28B | 14.08% |
| Mar 31, 2022 | 151.10B | 7.06B | 4.90% |
| Mar 31, 2021 | 144.04B | 1.50B | 1.06% |
| Mar 31, 2020 | 142.53B | 10.88B | 8.26% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
| Fortis Healthcare | 75.61B |
Zydus Lifesciences News
- 1 day ago - Zydus Medtech, Braile Biomedica sign global licensing pact to commercialise advanced TAVI technology - Business Upturn
- 1 day ago - Zydus Lifesciences confirms losing US patent case to Astellas in mirabegron litigation - Business Upturn
- 1 day ago - Zydus Lifesciences shareholder commitments in tender offer for Amplitude Surgical - Business Upturn
- 2 days ago - Zydus down 5%, Lupin down nearly 4% as US court orders withdrawal of Myrbetriq drug - Business Upturn
- 2 days ago - Zydus Lifesciences shares drop over 2.5% after losing Myrbetriq patent case in US - Business Upturn
- 3 days ago - Stocks to watch today: Zydus, Aurobindo, HCL Tech, Tata Power, Indian Hotels, Cyient in focus on expansion and global deals - Business Upturn
- 4 days ago - Top Stocks to watch on April 15: Ircon, Zydus, Ashoka Buildcon, Tata Power, Macrotech, Cyient in focus as markets reopen after long weekend - Business Upturn
- 7 days ago - Zydus Lifesciences receives USFDA approval for Jaythari (Deflazacort) Tablets across four strengths - Business Upturn